SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer

August 27, 2019 updated by: Zhi Li, People's Hospital of Zhengzhou University
In this study, the investigators detected the expression of SREBP1 in thyroid cancer tissues, explored the biological functions of SREBP1 in thyroid cancer cells.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

qRT-PCR and immunohistochemistry were used to detect the expression of SREBP1 in 96 pairs thyroid cancer tissues and the adjacent normal tissues. The following methods, including the MTS, colony-forming assay, flow cytometry and hoechst staining were used to detect the biological function of thyroid cancer cells based on SREBP1 interference or not.

Study Type

Observational

Enrollment (Actual)

140

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hunan
      • Changsha, Hunan, China, 410078
        • the Affiliated Cancer Hospital of Xiangya Medical School

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

all of this patients were recruited from the Affiliated Cancer Hospital of Xiangya Medical School

Description

Inclusion Criteria:

Clinical diagnosis of thyroid cancer Reciving thyroidectomy surgery No experience of radiation therapy Nice treatment compliance and follow-up regularly

Exclusion Criteria:

Prior history of malignancy ; Radiotherapy history, chemotherapy history; Serious concomitant diseases ; Chronic renal insufficiency and liver dysfunction

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
thyroid cancer
the thyroid cancer was determined by the the Pathology Department based on the pathological evidence.
Other: pathologic
All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
Other Names:
  • radioiodine
the adjacent thyroid tissues
the adjacent thyroid tissues was collected from the tissue that 3 centimeters from the thyroid cancer.
Other: pathologic
All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
Other Names:
  • radioiodine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
progression-free survival
Time Frame: average 5 years
disease recurrent of progression
average 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
theraputic efficacy
Time Frame: average 18 months
According to the ATA guideline, patients were divided into four group, including excellent response (ER),indeterminate response (IDR), biochemical incomplete response (BIR), structural incomplete response (SIR) after surgery and radioiodine treatment.
average 18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

People's Hospital of Zhengzhou University

Investigators

  • Principal Investigator: Zhi Li, Prof., Central South University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 16, 2016

Primary Completion (ACTUAL)

July 30, 2017

Study Completion (ACTUAL)

January 1, 2018

Study Registration Dates

First Submitted

January 16, 2018

First Submitted That Met QC Criteria

August 27, 2019

First Posted (ACTUAL)

August 28, 2019

Study Record Updates

Last Update Posted (ACTUAL)

August 28, 2019

Last Update Submitted That Met QC Criteria

August 27, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SBQLL-2016-015

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thyroid Cancer

Clinical Trials on pathologic

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe